A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with a Solid Tumor Cancer

ID Number 16-0263

Principal Investigator(s)
Joshua Brody

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to determine the dose and dosing schedule of an experimental drug called MEDI9197

Contact Information
Hoda Bashir
(212) 824-7309

Recruiting Patients: Yes